Anti-Coagulants - Peru

Peru

Peru's Anti-Coagulants market is estimated to generate a revenue of US$35.74m in 2024.
This sector is expected to experience a steady annual growth rate (CAGR 2024-2029) of 7.45%, leading to a market volume of US$51.18m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$16,740.00m in 2024.
Peru's anti-coagulant market is witnessing a surge in demand due to the aging population and increasing prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Peru is experiencing steady growth due to various factors.

Customer preferences: Peruvian customers have shown a preference for oral anti-coagulants over injectables due to their ease of use and convenience. This trend is in line with the global market, where oral anti-coagulants have been gaining popularity over the years. Additionally, patients in Peru tend to prefer generic drugs over branded ones due to their affordability.

Trends in the market: The Anti-Coagulants market in Peru is expected to experience significant growth in the coming years due to the increasing prevalence of cardiovascular diseases. The aging population is also a contributing factor to the growth of the market, as the risk of developing cardiovascular diseases increases with age. Furthermore, the COVID-19 pandemic has led to an increase in the number of patients with blood clotting disorders, which has further boosted the demand for anti-coagulants.

Local special circumstances: The Peruvian government has implemented various policies to improve access to healthcare, including the provision of free healthcare services to low-income families. This has led to an increase in the demand for anti-coagulants, as more people are able to afford treatment for cardiovascular diseases. However, the lack of awareness about the importance of preventive healthcare measures remains a challenge in Peru.

Underlying macroeconomic factors: Peru has been experiencing steady economic growth over the years, which has led to an increase in the country's healthcare expenditure. The government has also been investing in the healthcare sector to improve access to healthcare services. These factors have contributed to the growth of the Anti-Coagulants market in Peru. However, the country's political instability and corruption remain a challenge for businesses operating in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.